Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.98 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 Next >

This New Mountain Finance Analyst Turns Bearish; Here Are Top 3 Downgrades For Monday ↗

September 15, 2025

Via Benzinga

Unusual volume stocks in Thursday's session ↗

September 11, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark ↗

September 10, 2025

U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud...

Via Chartmill

Topics Economy

Let's take a look at the stocks that are in motion in today's session. ↗

September 09, 2025

Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened ↗

September 09, 2025

Via Stocktwits

Dow Surges Over 100 Points; Korn Ferry Earnings Top Views ↗

September 09, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 09, 2025

Via Benzinga

Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday ↗

September 09, 2025

Via Benzinga

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗

September 09, 2025

Novartis agreed to buy a cardiovascular-focused biotech company

Via Investor's Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗

September 09, 2025

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.

Via Investor's Business Daily

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition ↗

September 09, 2025

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 09, 2025

Via Benzinga

Why Nebius Group Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2025

Via Benzinga

Tourmaline Bio Reports Loss as R&D Rises ↗

August 13, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 23, 2025

Via Benzinga

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings ↗

May 20, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 20, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 20, 2025

Via Benzinga

What's going on in today's pre-market session ↗

April 17, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 17, 2025

Via Benzinga

This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗

March 06, 2025

Via Benzinga

This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

February 24, 2025

Via Benzinga

TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024 ↗

August 08, 2024

TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024 ↗

May 13, 2024

TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 21, 2024

Via Benzinga

Dow Jumps 200 Points; US Weekly Jobless Claims Fall ↗

March 21, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose...

Via Benzinga

Topics Stocks

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 21, 2024

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Via Benzinga

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results ↗

March 21, 2024

Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 21, 2024

Via Benzinga

Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 21, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

Via Benzinga

Topics Stocks

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.